PDPK1, one of the members of an upregulated EGF-signaling network in LRCC, mediates resistance to gemcitabine, is found to be dysregulated in pancreas cancer specimens, and might be an attractive molecular target for combination therapy studies. Here, PDPK1 is linked to hereditary leiomyomatosis and renal cell cancer.